ATE415397T1 - Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen - Google Patents

Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen

Info

Publication number
ATE415397T1
ATE415397T1 AT05755596T AT05755596T ATE415397T1 AT E415397 T1 ATE415397 T1 AT E415397T1 AT 05755596 T AT05755596 T AT 05755596T AT 05755596 T AT05755596 T AT 05755596T AT E415397 T1 ATE415397 T1 AT E415397T1
Authority
AT
Austria
Prior art keywords
prophylaxis
modulators
metabolism
treatment
substituted aryl
Prior art date
Application number
AT05755596T
Other languages
English (en)
Inventor
Robert Jones
Graeme Semple
Yifeng Xiong
Young-Jun Shin
Albert Ren
Juerg Lehmann
Beatriz Fioravanti
Marc Bruce
Jin Choi
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of ATE415397T1 publication Critical patent/ATE415397T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05755596T 2004-06-04 2005-06-02 Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen ATE415397T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57735404P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
ATE415397T1 true ATE415397T1 (de) 2008-12-15

Family

ID=34971499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05755596T ATE415397T1 (de) 2004-06-04 2005-06-02 Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen

Country Status (30)

Country Link
US (1) US20090036434A1 (de)
EP (1) EP1756084B1 (de)
JP (1) JP2008501698A (de)
CN (2) CN1997640A (de)
AR (1) AR049293A1 (de)
AT (1) ATE415397T1 (de)
AU (1) AU2005252211A1 (de)
BR (1) BRPI0511757A (de)
CA (1) CA2568451A1 (de)
CR (1) CR8741A (de)
CY (1) CY1108762T1 (de)
DE (1) DE602005011279D1 (de)
DK (1) DK1756084T3 (de)
EA (1) EA011671B1 (de)
EC (1) ECSP067066A (de)
ES (1) ES2320359T3 (de)
HR (1) HRP20090093T3 (de)
IL (1) IL179458A (de)
MX (1) MXPA06014129A (de)
NO (1) NO20065868L (de)
NZ (1) NZ552387A (de)
PE (1) PE20060530A1 (de)
PL (1) PL1756084T3 (de)
PT (1) PT1756084E (de)
RS (1) RS50755B (de)
SI (1) SI1756084T1 (de)
TW (1) TW200610528A (de)
UA (1) UA92150C2 (de)
WO (1) WO2005121121A2 (de)
ZA (1) ZA200610095B (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es) 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
NZ556017A (en) * 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006130986A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2308840A1 (de) * 2005-06-30 2011-04-13 Prosidion Limited GPCR-Agonisten
EP1931654B1 (de) * 2005-09-16 2009-04-22 Arena Pharmaceuticals, Inc. Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
BRPI0710597A2 (pt) * 2006-04-11 2012-06-19 Arena Pharm Inc método de uso do receptor gpr119 para identificar compostos úteis para aumento da massa óssea em um indivìduo
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
CA2661371A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyrimidine compounds for treating gpr119 related disorders
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
BRPI0719941A2 (pt) 2006-12-06 2014-04-22 Smithkline Beecham Corp Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
EA018709B1 (ru) 2007-07-17 2013-10-30 Бристол-Маерс Сквибб Компани Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
AU2008302570B2 (en) 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
BRPI0818338A2 (pt) * 2007-10-16 2015-04-22 Daiichi Sankyo Co Ltd Composto de pirimidil indolina
KR20100075643A (ko) 2007-10-22 2010-07-02 쉐링 코포레이션 비사이클릭 헤테로사이클 유도체 및 ｇｐｒ119의 활성의 조절인자로서의 이의 용도
WO2009063364A2 (en) * 2007-11-13 2009-05-22 Encysive Pharmaceuticals Inc. Modulators of urotensin receptor and methods of use thereof
KR20100120689A (ko) * 2008-02-22 2010-11-16 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
EP2108960A1 (de) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
US8343990B2 (en) 2008-04-14 2013-01-01 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010059384A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
US8722882B2 (en) 2008-12-23 2014-05-13 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
US8410122B2 (en) 2008-12-23 2013-04-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010085811A2 (en) * 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
EP2399914A4 (de) 2009-02-18 2012-08-29 Takeda Pharmaceutical Fusionierte heterozyklische ringverbindung
EP2408780A2 (de) * 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonane
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
WO2010119881A1 (ja) * 2009-04-15 2010-10-21 第一三共株式会社 インドリン化合物
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
JP2013511571A (ja) * 2009-11-23 2013-04-04 ファイザー・インク Ｇｐｒ１１９阻害剤としてのイミダゾ−ピラゾール
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
MX2012011460A (es) 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
RU2012154308A (ru) 2010-05-17 2014-06-27 Эррэй Биофарма Инк. Пиперидинил-замещенные лактамы как модуляторы gpr119
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
SG188548A1 (en) * 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
JO3145B1 (ar) 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
WO2013066869A1 (en) * 2011-11-03 2013-05-10 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
IN2014KN02601A (de) 2012-04-24 2015-05-08 Vertex Pharma
EP2850073B1 (de) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridon-analoga als gpr119-modulatoren
SMT202100687T1 (it) 2013-03-12 2022-01-10 Vertex Pharma Inibitori della dna-pk
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
AR098394A1 (es) * 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
LT3177612T (lt) * 2014-08-04 2022-06-10 Nuevolution A/S Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
KR20190015535A (ko) 2016-06-09 2019-02-13 프라마나 파마슈티컬스 인크. 벤조[d][1,3]옥사티올, 벤조[d][1,3]옥사티올 3-옥사이드 또는 벤조[d][1,3]옥사티올 3,3-디옥사이드를 함유하는 화합물 및 Ｇ 단백질 커플링된 수용체 119의 작용제로서 이의 방법/용도
EP3518931A4 (de) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated Verfahren zur behandlung von krebs mit einer kombination aus dna-schädigenden substanzen und dna-pk-inhibitoren
AU2018218518B2 (en) 2017-02-07 2022-03-17 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
RU2019128063A (ru) 2017-02-07 2021-03-09 Облик Терапьютикс Аб Углеводородсульфонилзамещенные пиридины и их применение при лечении рака
BR112019016223A2 (pt) 2017-02-07 2020-04-07 Oblique Therapeutics Ab piridinas substituídas por heteroarilsulfonila e uso das mesmas no tratamento de câncer
MX389800B (es) 2017-02-07 2025-03-20 Oblique Therapeutics Ab Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
MX388196B (es) 2017-04-26 2025-03-19 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
MA49456A (fr) 2017-06-19 2020-04-29 Arena Pharm Inc Composés et procédés pour le traitement de nafld et de nash
US11358956B2 (en) 2017-11-30 2022-06-14 Pramana Pharmaceuticals Inc. Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
RS65019B1 (sr) 2019-05-10 2024-01-31 Deciphera Pharmaceuticals Llc Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
AU2020274011B2 (en) 2019-05-10 2024-02-15 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
CN119241444A (zh) 2019-06-17 2025-01-03 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
TWI872177B (zh) * 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH478817A (de) * 1965-10-22 1969-09-30 Ciba Geigy Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de) * 1967-01-09 1969-10-31 Geigy Ag J R Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) * 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
US3608087A (en) * 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) * 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) * 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3690834A (en) * 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
US3966744A (en) * 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
DE2106585A1 (de) * 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazole und Thiodiazol-Azofarbstoffe
US3966764A (en) * 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) * 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (de) * 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (de) * 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azofarbstoffe
AT340933B (de) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US4101541A (en) * 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
FR2306697A1 (fr) * 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
DE2731264A1 (de) * 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) * 1977-12-09 1985-09-02 コニカ株式会社 ハロゲン化銀カラ−写真感光材料
US4242507A (en) * 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (de) * 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung von Glycerin
DE2906603A1 (de) * 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
DE3334455A1 (de) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3601196A1 (de) * 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
DE69532811T2 (de) * 1994-09-09 2005-03-17 Nippon Shinyaku Co., Ltd. Heterocyclische Derivative und Arzneimittel
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) * 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6008234A (en) * 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
CA2317017A1 (en) * 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6239126B1 (en) * 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
IL148385A0 (en) * 1999-09-10 2002-09-12 Merck & Co Inc Tyrosine kinase inhibitors
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
DE60208792T2 (de) * 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
HUP0401711A3 (en) * 2001-06-26 2009-07-28 Bristol Myers Squibb Co N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
AU2003285007A1 (en) * 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
KR101078098B1 (ko) * 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
AU2004218456A1 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists.
US7083933B1 (en) * 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005077938A1 (en) * 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Also Published As

Publication number Publication date
ES2320359T3 (es) 2009-05-21
MXPA06014129A (es) 2007-03-07
PL1756084T3 (pl) 2009-06-30
PT1756084E (pt) 2009-02-17
PE20060530A1 (es) 2006-06-28
UA92150C2 (ru) 2010-10-11
WO2005121121A2 (en) 2005-12-22
ZA200610095B (en) 2008-05-28
AU2005252211A1 (en) 2005-12-22
AR049293A1 (es) 2006-07-12
WO2005121121A3 (en) 2006-03-16
RS50755B (sr) 2010-08-31
DE602005011279D1 (de) 2009-01-08
CY1108762T1 (el) 2014-04-09
JP2008501698A (ja) 2008-01-24
CN1997640A (zh) 2007-07-11
CR8741A (es) 2007-08-28
US20090036434A1 (en) 2009-02-05
EA011671B1 (ru) 2009-04-28
NO20065868L (no) 2007-02-16
NZ552387A (en) 2010-10-29
EP1756084A2 (de) 2007-02-28
CA2568451A1 (en) 2005-12-22
HRP20090093T3 (en) 2009-03-31
ECSP067066A (es) 2007-01-26
SI1756084T1 (sl) 2009-04-30
CN101870690A (zh) 2010-10-27
DK1756084T3 (da) 2009-03-23
HK1097271A1 (en) 2007-06-22
IL179458A (en) 2011-04-28
BRPI0511757A (pt) 2008-01-08
TW200610528A (en) 2006-04-01
EA200602179A1 (ru) 2007-04-27
EP1756084B1 (de) 2008-11-26
IL179458A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE380809T1 (de) Trisubstituiertes aryl- und heteroarylderivate als stoffwechselmodulatoren und die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE381558T1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP1940437A4 (de) Zusammensetzungen und verfahren zur behandlung von bakterien
EP1742675A4 (de) Behandlung von biomedizinischem abfall
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
EP1804787A4 (de) Flavonoidzusammensetzung zur behandlung oraler erkrankungen
ATE529427T1 (de) Ä1h-indol-5-yl)-heteroaryloxyü-(1-aza-bicyclo- ä3.3.1ü-nonane als cholinergische liganden des n- achr zur behandlung psychotischer und neurodegenerativer leiden
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
EP1843773A4 (de) Verfahren und zusammensetzung zur behandlung von neoplasien
DE602005027388D1 (de) Malonsäureamidderivate als inhibitoren von g-sekretase zur behandlung von alzheimer-krankheit
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE542804T1 (de) 5-phenyl-pentansäurederivate als matrixmetalloproteinase-inhibitoren zur behandlung von asthma und anderen erkrankungen
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1756084

Country of ref document: EP